With this new posting on “Schizophrenia News Watch” – we are initiating a periodic summary of interesting schizophrenia-related news from around the globe. In these postings we will provide short summaries and links to schizophrenia-related news, videos and presentations from around the world.
Closer than ever to a cure for Schizophrenia: This is a good radio interview with Cyndi Wickert, a schizophrenia-focused professor and researcher that now resides and works in Australia, but who grew up in upstate New York. Cindy has a brother who has schizophrenia.
Professor Wickert has made important contributions to the conceptualization of schizophrenia as a neurodevelopmental disorder and is best known for her pioneering work on brain-derived neurotropic factor (BDNF) and the estrogen receptor. She is Macquarie Group Foundation Chair of Schizophrenia Research, a joint position between NeuRA, UNSW and Schizophrenia Research Institute.
Click here to listen to the full interview: Cyndi Wickert Interview on ABC
Metformin May Help Combat Antipsychotic-Induced Weight Gain – We have reported in the past (6 years ago in this report – “Antipsychotic Drug-induced weight gain stopped with metformin” about the benefits of metformin for people taking anti-psychotic medications. Here is yet another report on this well-proven, and inexpensive medicine (its been available as a generic medication for many years all around the world). In this new news it is reported that:
“Despite its modest ability to attenuate weight gain, metformin may be an important addition for patients at risk for weight gain associated with antipsychotics and related consequences.
In a new meta-analysis, researchers have found the drug metformin appears to be the most effective pharmacological option for countering weight gain related to the use of antipsychotic medications. Metformin is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes.”
Read the full story here: Metformin May Help Combat Antipsychotic-Induced Weight Gain
More about Metformin on Wikipedia: Metformin
Cognitive Behavioral Therapy (CBT) for Psychosis (Schizophrenia) – Lessons from History and Hopes for the Future
CBT for schizophrenia is the most-recommended psychological approach to improving outcomes in people who have schizophrenia. In the UK / England it is recommended by the National Health Service for everyone who has schizophrenia, and for front-line treatment starting as soon as the person is identified as suffering from schizophrenia. We’ve covered it many times in the past – and you can read some of those news stories and interviews here:
Web Software that teaches CBT for Schizophrenia (Copingtutor.com) – associated with founder of Schiz.com.
In this new overview on CBT for schizophrenia, out of Australia, it suggests:
“Evidence from the first randomised controlled trials of CBT for psychosis were promising, demonstrating significant improvement in target symptoms after brief intervention. A series of clinical manuals were developed showing how to apply CBT approaches to psychotic symptoms, followed in the early 2000s by positive meta-analyses (e.g., Gould, et al., 2001). More recently, CBT targeting psychosis has begun to be routinely delivered in a range of settings (individual, group, first episode, acute phase etc). The sense of therapeutic nihilism has lifted, with optimism reinforced by the inclusion of CBT for psychosis by the UK National Institute for Health and Clinical Excellence (NICE) guidelines (www.nice.org.uk/nicemedia/pdf/CG82NICEGuideline.pdf)”
“Today, the role of psychological intervention in the management of psychotic symptoms is an established component of treatment. ”
The overview also provides a good summary of some of the CBT working approaches for people with schizophrenia – something that every family could benefit from knowing. While these suggestions are for psychotherapists – we think that many families could benefit from knowing them also. Here is a brief look at these suggestions:
|CBT suggestions (to clinicians) for working with psychotic symptoms|
People who Experience Adderall Euphoria Less Likely to Develop ADHD, Schizophrenia – People with a genetic variant that results in euphoria-like feelings after taking d-amphetamine (the active ingredient in Adderall) have a reduced risk for developing attention deficit hyperactivity disorder (ADHD) and schizophrenia, according to scientists from the University of Chicago.
The findings, published in the journal Proceedings of the National Academy of Sciences, add to the long-standing evidence that dopamine — the neurotransmitter responsible for the euphoric feeling of amphetamine — is related to schizophrenia and ADHD
read full story: here
Brain Region linked to Schizophrenia – Researchers have identified a region of the brain which is sensitive to small changes in memory. The results provide a clue as to why this area is often found to be abnormal in people suffering with schizophrenia.
On bitopertin and sharing data from clinical trials
“one wonders, why didn’t a brand new bitopertin study (ClinicalTrials.gov identifier NCT00616798), with a solid design and impressive action on negative symptoms get any attention – from the media, psychiatrist gurus, patient’s advocates, anyone? The study, which just came out in the flagship psychiatric journal (JAMA Psychiatry) generated no press/media coverage that I am aware off.
Actually, this rather surprising silent treatment is not an accident.
It turns out that this study has been preempted by a press announcement that Roche made this last January stating that bitopertin did not hold up to its promise following its Phase III testing. Meaning that… the just published JAMA Psychiatry study — the very study which generated enough enthusiasm to justify the seemingly well-deserved promotion bitopertin received further down the pipeline — is old, outdated news.
To summarize: on one hand, great positive results from a just published study, which, as it turns out, are actually quite old. On the other hand, negative results in Phase III testing, according to a news conference, but no publications to date.
The result: bitopertin is at the center of what is essentially a skewed and likely misleading state of affairs – at least from the point of view of official scientific validation via publication in peer reviewed journals.”
Read the full story here: On bitopertin and sharing data from clinical trials (PLOS blogs)
This site does not provide medical or any other health care or fitness advice, diagnosis, or treatment. The site and its services, including the information above, are for informational purposes only and are not a substitute for professional medical or health advice, examination, diagnosis, or treatment.
Always seek the advice of your physician or other qualified health professional before starting any new treatment, making any changes to existing treatment, or altering in any way your current exercise or diet regimen. Do not delay seeking or disregard medical advice based on information on this site.
Medical information changes rapidly and while Schizophrenia.com makes efforts to update the content on the site, some information may be out of date.
No health information on Schizophrenia.com, including information about herbal therapies and other dietary supplements, is regulated or evaluated by the Food and Drug Administration and therefore the information should not be used to diagnose, treat, cure, or prevent any disease without the supervision of a medical doctor.